SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Septerna Selects SEP-204 as Development Candidate and Reports Preclinical Data

Septerna selected SEP-204 as a development candidate for Graves' disease and TED and reported preclinical data at the 2026 American Thyroid Association Annual Meeting.

SEPN

Related stories